Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy
| Autor: | Jörg Hüser, Lisa Dietz, Alexandros Vakalopoulos, Roland Seifert, Ilka Mathar, Peter Sandner, Shalini M Krishnan, Petra Haning, Elke Hartmann, Johannes Nordlohne |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Myeloid Duchenne muscular dystrophy Endogeny Grip strength Mice mdx/mTRG2 mice 0302 clinical medicine Soluble Guanylyl Cyclase Fibrosis Biology (General) Spectroscopy General Medicine Computer Science Applications skeletal muscle damage Chemistry medicine.anatomical_structure medicine.symptom medicine.medical_specialty QH301-705.5 Enzyme Activators skeletal muscle function Inflammation Mice Transgenic Catalysis Article Inorganic Chemistry 03 medical and health sciences Immune system Internal medicine medicine Animals Physical and Theoretical Chemistry Muscle Skeletal Molecular Biology QD1-999 duchenne muscular dystrophy business.industry sGC stimulator Organic Chemistry fibrosis Skeletal muscle medicine.disease Muscular Dystrophy Duchenne 030104 developmental biology Endocrinology inflammation Mice Inbred mdx business 030217 neurology & neurosurgery |
| Zdroj: | International Journal of Molecular Sciences Volume 22 Issue 15 International Journal of Molecular Sciences, Vol 22, Iss 8016, p 8016 (2021) |
| ISSN: | 1422-0067 |
| DOI: | 10.3390/ijms22158016 |
| Popis: | Duchenne muscular dystrophy (DMD) is a severe and progressive muscle wasting disorder, affecting one in 3500 to 5000 boys worldwide. The NO-sGC-cGMP pathway plays an important role in skeletal muscle function, primarily by improving blood flow and oxygen supply to the muscles during exercise. In fact, PDE5 inhibitors have previously been investigated as a potential therapy for DMD, however, a large-scale Phase III clinical trial did not meet its primary endpoint. Since the efficacy of PDE5i is dependent on sufficient endogenous NO production, which might be impaired in DMD, we investigated if NO-independent sGC stimulators, could have therapeutic benefits in a mouse model of DMD. Male mdx/mTRG2 mice aged six weeks were given food supplemented with the sGC stimulator, BAY-747 (150 mg/kg of food) or food alone (untreated) ad libitum for 16 weeks. Untreated C57BL6/J mice were used as wild type (WT) controls. Assessments of the four-limb hang, grip strength, running wheel and serum creatine kinase (CK) levels showed that mdx/mTRG2 mice had significantly reduced skeletal muscle function and severe muscle damage compared to WT mice. Treatment with BAY-747 improved grip strength and running speed, and these mice also had reduced CK levels compared to untreated mdx/mTRG2 mice. We also observed increased inflammation and fibrosis in the skeletal muscle of mdx/mTRG2 mice compared to WT. While gene expression of pro-inflammatory cytokines and some pro-fibrotic markers in the skeletal muscle was reduced following BAY-747 treatment, there was no reduction in infiltration of myeloid immune cells nor collagen deposition. In conclusion, treatment with BAY-747 significantly improves several functional and pathological parameters of the skeletal muscle in mdx/mTRG2 mice. However, the effect size was moderate and therefore, more studies are needed to fully understand the potential treatment benefit of sGC stimulators in DMD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |